Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 11/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549384 | 0.89 | PPARG (0.49) | MMP2MMP3PPARGPPARAATM | |
| SCHEMBL21528815 | 0.85 | MMP2 (0.50) | MMP2MMP3PPARGPPARAFFAR2 | |
| SCHEMBL14430204 | 0.85 | ATM (0.50) | PPARGPPARAATMCTSKCTSS | |
| SCHEMBL4659427 | 0.85 | ATM (0.50) | PPARGPPARAATMCTSKCTSS | |
| SCHEMBL21528813 | 0.85 | MMP2 (0.50) | MMP2MMP3PPARGPPARAFFAR2 | |
| SCHEMBL13970938 | 0.84 | PPARG (0.49) | PPARGPPARAATMCTSKCTSS | |
| SCHEMBL12766379 | 0.84 | PPARG (0.49) | PPARGPPARAATMCTSKCTSS | |
| SCHEMBL1519701 | 0.83 | ATM (0.51) | PPARGPPARAATMCTSKCTSS | |
| SCHEMBL1595057 | 0.82 | ATM (0.52) | PPARGPPARAATMCTSKCTSS | |
| SCHEMBL28800338 | 0.82 | ATM (0.65) | ATMCTSKCTSSACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| US-11384060-B2 | Amide compounds and use thereof | ALPHALA CO., LTD. (TW) | 2022-07-12 | — | — | US | disclosed |
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO., LTD. (TW) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337915-A1 | AMIDE COMPOUNDS AND USE THEREOF | GLP1R, IAPP, GPR119 | MMP2 2087/4885MMP3 3257/4885PPARG 93/4885 |
| US-11384060-B2 | Amide compounds and use thereof | GLP1R, IAPP, GPR119 | MMP2 2087/4885MMP3 3257/4885PPARG 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.